GSK (FRA:GS70) Total Receivables: €8,945 Mil (As of Mar. 2026)


FRA:GS70 GSK PLC FRA:GS70
82 GF Score
Price €46.40
GF Value €38.09
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is GSK Total Receivables?

GSK FRA:GS70 +5.94% 82 Total Receivables is €8,945 Mil as of Mar. 2026. GuruFocus rates FRA:GS70 with a GF Score™ of 82/100 and a GF Value™ of €38.09 (Modestly Overvalued). The stock has 3 warning signs investors should review.

GSK's Total Receivables for the quarter that ended in Mar. 2026 was €8,945 Mil.

GSK Total Receivables Historical Data

* Premium members only.

The historical data trend for GSK's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Total Receivables Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,879.42 7,149.56 7,504.31 7,242.79 7,516.80

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8,436.14 8,612.36 9,138.28 7,516.80 8,945.25
FRA:GS70
82GF Score
GSK PLC FRA:GS70
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €8,945 Mil mean?
GSK (FRA:GS70) has a Total Receivables of €8,945 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GSK and its competitors.
Is GSK's Total Receivables too high?
GSK's current Total Receivables is €8,945 Mil. Overall, GSK has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Total Receivables compare to LLY and JNJ?
GSK's Total Receivables of €8,945 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on GSK and its competitors. GSK's current Total Receivables is €8,945 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (FRA:GS70) is currently considered Modestly Overvalued. The stock's GF Value™ is €38.09, compared to a current price of €46.40 — trading 21.8% above its estimated fair value. The current Total Receivables is €8,945 Mil. GSK's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For GSK (FRA:GS70), the current Total Receivables is €8,945 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (FRA:GS70) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of €46.40 is trading 21.8% above its estimated GF Value™ of €38.09. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for FRA:GS70:

  • Total Receivables: €8,945 Mil
  • GF Value™: €38.09 vs. price of €46.40 (21.8% above fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the FRA:GS70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
82GF Score

Get the complete analysis for FRA:GS70

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.40
Price
€38.09
GF Value